HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Acute hepatitis — Clinical Guidelines

Overview

Acute hepatitis encompasses a spectrum of liver inflammation, often viral in origin but can also result from non-viral causes such as tropical infections and other pathogens. Recent outbreaks highlight the importance of identifying unknown etiologies, particularly in pediatric populations 1 3.

Diagnosis

Clinical Presentation: Jaundice, abdominal pain, nausea, vomiting, and sometimes persistent fever and skin rashes (indicative of tropical infections) 2.

Laboratory Tests: Elevated liver enzymes (ALT, AST), bilirubin levels, and often thrombocytopenia in tropical infection cases 2.

Imaging: Not typically required but may show hepatomegaly 3.

Liver Biopsy: Useful for assessing severity and presence of piecemeal necrosis, which predicts chronicity in hepatitis B and non-A, non-B cases 8.

Viral Testing: Include tests for adenovirus, hepatitis A, B, C, E, and others as indicated; high prevalence of adenovirus in recent cases 3 4.

Autoantibody Screening: Consider testing for autoantibodies against vimentin in suspected non-A, non-B hepatitis 6.

Management

Supportive Care: Fluid management, nutritional support, and monitoring for complications 3.

Interferon Treatment: Consider in fulminant cases; human interferon-alpha at doses of 3 x 10^6 u/day (70,000 u/kg per day for infants) for up to 8 days 5.

Specific Antiviral Therapy: Tailored to identified viral etiology (e.g., antiviral agents for hepatitis B or C) 4.

Liver Transplantation: Indicated for severe cases with impending liver failure or encephalopathy 3.

Special Populations

Pediatrics: Higher incidence in children <6 years; adenovirus implicated in many cases 3.

Pregnancy: Interferon treatment outcomes vary; caution advised due to potential risks 5.

Elderly: Higher prevalence of hepatitis C with increasing age 4.

Comorbidities: No specific guidance provided; manage based on underlying conditions and liver function 3.

Key Recommendations

High Index of Suspicion for Tropical Infections in patients with persistent fever and jaundice, especially with skin rash and thrombocytopenia (Evidence: Moderate) 2.

Consider Adenovirus Testing in cases of acute hepatitis of unknown etiology, particularly in pediatric patients (Evidence: Moderate) 3 4.

Evaluate for Piecemeal Necrosis in liver biopsies to predict risk of chronicity in hepatitis B and non-A, non-B cases (Evidence: Moderate) 8.

Use Interferon-Alpha in fulminant cases of acute hepatitis with caution, especially in pregnant women (Evidence: Weak) 5.

Supportive Care and Monitoring remain cornerstone in managing acute hepatitis until etiology is identified (Evidence: Expert opinion) 3.

References

1 Zeng F, Liu Q, Wang X, Zhong P, Wu P, Yang M et al.. Immunoinformatics design and experimental expression of a multi-epitope vaccine simultaneously targeting AAV2 and HAdV-F41 against acute hepatitis of unknown etiology. Virology 2025. link 2 Samanta A, Poddar U, Sen Sarma M, Srivastava A, Yachha SK, Mishra P. Persistent fever in acute hepatitis: think beyond acute viral hepatitis. Infectious diseases (London, England) 2024. link 3 Indolfi G, Czubkowski P, Fitzpatrick E, Gonzales E, Gupte G, Mancell S et al.. Acute Hepatitis of Unknown Etiology Among Young Children: Research Agenda by the ESPGHAN Hepatology Committee. Journal of pediatric gastroenterology and nutrition 2022. link 4 Chu CM, Lin SM, Hsieh SY, Yeh CT, Lin DY, Sheen IS et al.. Etiology of sporadic acute viral hepatitis in Taiwan: the role of hepatitis C virus, hepatitis E virus and GB virus-C/hepatitis G virus in an endemic area of hepatitis A and B. Journal of medical virology 1999. link1096-9071(199906)58:2<154::aid-jmv9>3.0.co;2-e) 5 Levin S, Leibowitz E, Torten J, Hahn T. Interferon treatment in acute progressive and fulminant hepatitis. Israel journal of medical sciences 1989. link 6 Brown C, Pedersen J, Underwood JR, Gust I, Toh BH. Autoantibodies to intermediate filaments in acute viral hepatitis A, B and non-A, non-B are directed against vimentin. Journal of clinical & laboratory immunology 1986. link 7 Reddy KR, Farnum JB, Thomas E. Acute hepatitis associated with campylobacter colitis. Journal of clinical gastroenterology 1983. link 8 Vanstapel MJ, van Steenbergen W, de Wolf-Peeters C, Desmyter J, Fevery J, de Groote J et al.. Prognostic significance of piecemeal necrosis in acute viral hepatitis. Liver 1983. link 9 Bortolotti F, Cadrobbi P, Carretta M, Meneghetti F, Pornaro E, Realdi G. Epidemiological aspects on acute viral hepatitis in northern Italy. Scandinavian journal of infectious diseases 1982. link

Acute hepatitis